Highly Concentrated Gingeroids


Formulated with CO2 Extract of Ginger Rhizome

Highly Concentrated Gingeroids


Formulated with CO2 Extract of Ginger Rhizome
Ginfort® is the ultimate evolution of ginger. Ginfort® delivers the highest available gingeroid polyphenol content, at 26% total gingerols and shogaols, on the backdrop of cutting-edge clinical and safety data. This unique portfolio advances the trusted kitchen remedy beyond known limitations of having a high dose requirement, low solubility and anecdotal use-history, to an active that is convenient to take, solubility-enhanced and proven both safe and effective.

Ginger use dates back to as early as 400 BC, as both a culinary and medicinal spice in Asian cultures. Its primary therapeutic use involved remedying various upper gastrointestinal system issues, from dyspepsia and gastritis to indigestion and nausea. Ginger’s volatile oils, contributing at only 2-3% of the rhizome’s total composition, have been identified as the active involved in providing this relief. Though gingeroids (gingerols and shogaols) naturally make up about 50% of ginger’s volatile oil content, their overall low assay, lack of stability and lipophilic nature have resulted in limited clinical evidence, or evidence only with very high dosing (e.g. 2-4 g/day).

Ginfort® delivers more than 12X the gingeroid and 6-gingerol content of traditional ginger rhizome preparations, without any solvents and with a proven stability, above specification over 2+ years.

The patented Ginfort® advantage is availed from the application of Aqueosome® technology. This platform enhances the solubility of lipophilic gingeroids from the ginger oleoresin through the patented application of a blend of safe, food-grade inactives. This innovative step frees Ginfort® from consumer-adverse bioenhancers like polysorbate and PVP, as well as absolving it from the unrestrained use of maltodextrin, as is common in spray-dried formats.


Gingeroids have carminative action – reducing gas, flatulence and bloating. They are also proposed to act as a prokinetic, promoting synchronized peristalsis, over dysfunctional stomach and small intestine motility – common abnormalities at the root of functional dyspepsia.

Ginfort®, taken in 200 mg capsules 2-times/day, was trialed in a 28-day double-blind, randomized controlled trial in subjects with Functional Dyspepsia. Interim benefits were also assessed at day 14 for a primary outcome of overall treatment efficiency as measured on a 7 point Likert Scale and secondarily, the elimination rate for three primary functional dyspepsia symptoms. Safety data was also collected and it was concluded that Ginfort® intake was without consequence on any safety parameter.


Ginfort® is a registered trademark of Olene Life Sciences Pvt. Ltd., exclusively licensed to DolCas Biotech, LLC.
Aqueosome® is a registered trademark of Olene Life Sciences Pvt. Ltd.

Applications

Your Subtitle Goes Here
3
  • Powder for encapsulation
  • Lozenges, candies

Benefits

Your Subtitle Goes Here
3
  • Supports gut health
  • Promotes healthy digestion
  • Improves upper-abdominal bloating
  • Reduces digestive upset
  • Relieves excessive belching
  • Helps occasional heartburn symptoms
  • Supports joint health*
  • Improves nausea and vomiting*
  • Helps pregnancy sickness*

* Generally supported by the literature

Composition

Your Subtitle Goes Here
3
Ginfort® is the most concentrated gingerol formulation on the market, boasting a 26% gingerol content, of which half of that are stabilized in the 6-gingerol form. Ginfort® is derived from the ginger oleoresin, which comprises 60% of the ingredient. A patented blend of food-grade inactives are added to this CO2-extracted base to allow for improved solubility and flow.

Safety

Your Subtitle Goes Here
3
Ginfort® has been subjected to a battery of safety studies directed by OECD guidelines, with no suggested toxicity at recommended clinical and exaggerated doses. The studies include acute oral toxicity study, acute dermal irritation study, acute eye irritation study, genotoxicity and mutagenicity studies, a 14-day repeated dose range finding study, and a 90-day repeated dose toxicity study.

Clinical Research

Your Subtitle Goes Here
3
Ginfort® was subjected to a 28-day, double-blind, randomized controlled trial in subjects with Functional Dyspepsia. The study has been accepted for publication in the Journal of Dietary Supplements in the first quarter of 2021.

Want to Learn More?

Please leave us your contact information below for a free brochure.

Please select which product(s) you are interested in.

8 + 11 =

Our Products